Invention Grant
US09278970B2 Co-crystals of tadalafil and a hydroxy-substituted benzoic acid coformer as phosphodiesterase type 5 inhibitors
有权
作为磷酸二酯酶5型抑制剂的他达拉非和羟基取代的苯甲酸共成形物的共晶体
- Patent Title: Co-crystals of tadalafil and a hydroxy-substituted benzoic acid coformer as phosphodiesterase type 5 inhibitors
- Patent Title (中): 作为磷酸二酯酶5型抑制剂的他达拉非和羟基取代的苯甲酸共成形物的共晶体
-
Application No.: US14412272Application Date: 2013-07-06
-
Publication No.: US09278970B2Publication Date: 2016-03-08
- Inventor: Dea Herrera Ruiz , Karina Mondragón Vásquez , Hugo Morales Rojas , Herbert Höpfl , Juan Pablo Senosiain Peláez
- Applicant: Laboratorios Senosiain S.A. de C.V.
- Applicant Address: MX Mexico City
- Assignee: Laboratorios Senosiain S.A. de C.V.
- Current Assignee: Laboratorios Senosiain S.A. de C.V.
- Current Assignee Address: MX Mexico City
- Agent Stephen S. Hodgson
- Priority: MXMX/a/2012/007915 20120706
- International Application: PCT/IB2013/055530 WO 20130706
- International Announcement: WO2014/006604 WO 20140109
- Main IPC: C07D241/38
- IPC: C07D241/38 ; C07D471/14
Abstract:
The present invention relates to co-crystals of tadalafil with hydroxyl-substituted benzoic acid coformers having the following structure. Said co-crystals can be used to produce a pharmaceutical composition containing the same as the useful active ingredient. Said co-crystals can exhibit a constant storage stability.
Public/Granted literature
- US20150152107A1 Novel Solid Forms of Phosphodiesterase Type 5 Inhibitors Public/Granted day:2015-06-04
Information query
